Merit Medical Systems Inc - MMSI STOCK NEWS

Merit Medical Systems (NASDAQ: MMSI) announced it will release its financial results for Q3 2022 on October 26, 2022, after the market close. An investor conference call is scheduled for the same day at 5:00 p.m. Eastern. Interested parties can pre-register for the call, and a live webcast will be available. Founded in 1987, Merit is a global leader in healthcare technology, employing over 6,900 individuals across multiple countries.

Merit Medical Systems has launched the TEMNO Elite™ Soft Tissue Biopsy System, designed to improve biopsy procedures. It provides 72% larger samples compared to competitors, ensuring better diagnostic accuracy. The device features Sample Assist™ technology for easier tissue retrieval and includes an optional valved coaxial introducer for enhanced patient safety. This innovation reinforces Merit’s commitment to advancing patient care and improving diagnostic processes in pathology labs.

Merit Medical Systems has launched the Prelude Roadster™ Guide Sheath in the U.S., enhancing access to difficult vascular anatomies. This device is crucial for treating the approximately 6.5 million Americans with Peripheral Artery Disease (PAD), a condition that impedes blood flow and raises the risk of serious complications. The Prelude Roadster aims to improve the deliverability and efficacy of medical procedures in challenging cases, demonstrating the company's commitment to patient care.

Merit Medical Systems (MMSI) reported Q2 2022 revenue of $295.0 million, reflecting a 5.2% increase from Q2 2021. Constant currency organic revenue grew 7.4%. The GAAP operating margin improved to 7.9% compared to 3.2% last year, with non-GAAP operating margin reaching 19.1%. GAAP EPS was $0.27, up from $0.09, and non-GAAP EPS rose to $0.73 from $0.62. Updated guidance for FY 2022 projects revenue between $1.123 billion to $1.135 billion, a 5% to 6% increase, with net income forecasted between $62.4 million to $68.3 million.

Merit Medical Systems has launched the Elation Pulmonary Balloon Dilator, the smallest configuration specifically designed for small airways in the U.S. market. This innovative product addresses a critical need in pulmonary care, enabling physicians to match balloon size to specific small airways, enhancing treatment options for patients with airway obstructions. The multi-stage balloon configuration also features a kink-resistant catheter, allowing for multiple dilations in one procedure. This development marks a significant advancement in minimally invasive treatments for lung conditions.

Merit Medical Systems, Inc. (NASDAQ: MMSI) will release its financial results for the quarter ending June 30, 2022, on July 27, 2022, after the market closes. An investor conference call is slated for the same day at 5:00 p.m. Eastern, providing insights into the company's performance. Merit specializes in proprietary disposable medical devices for various medical fields, employing approximately 6,500 people worldwide, with operations in multiple countries.

Merit Medical Systems (NASDAQ: MMSI) has initiated a prospective observational study in Canada to assess the effectiveness of the SCOUT® Radar Localization System in breast-conserving surgeries. The first patient has been enrolled in the study, which aims to include 500 patients and evaluate outcomes from the SCOUT procedure to surgery. The study is crucial for improving patient care, especially during the ongoing COVID-19 pandemic, and will examine safety, efficacy, and satisfaction levels among patients and clinicians.

Merit Medical Systems has launched the SCOUT Mini Reflector, an advanced device measuring 8 mm, which is 33% shorter than the standard SCOUT Reflector. This innovation enhances localization in challenging areas such as lymph nodes and is applicable during biopsy or pre-neoadjuvant chemotherapy. The SCOUT Mini offers superior directionality, improving accuracy to +/- 1 mm. It addresses over 300,000 new breast cancer cases diagnosed annually in the U.S., and supports multiple treatment scenarios. The SCOUT technology has been utilized in more than 275,000 procedures since 2015.

Merit Medical Systems (MMSI) has announced the successful enrollment of the first patient in the WRAP Registry Study, aimed at assessing the safety and efficacy of the WRAPSODY Cell-Impermeable Endoprosthesis for hemodialysis patients. This international study will enroll up to 500 patients facing vascular access issues due to stenosis or occlusion. It will monitor clinical outcomes over two years, providing critical real-world evidence that may enhance treatment options for over two million global dialysis patients suffering from vascular complications.